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The architects of phase I radiochemotherapy development programs impose a sem-
blance of structured radiation “intensity” and adverse event predictability upon radiation-
anticancer agent interactions whose natural complexity and improper mixing would other-
wise lead to dire health consequences. It is incumbent upon radiation oncology investiga-
tors to pledge radiation quality and safety to the participants of radiochemotherapy trials.
Measures of radiation quality and safety may be tools to scrutinize radiation-anticancer
agent dose and schedule, as well as, radiation field design among diverse radiation deliv-
ery platforms. In this article, the merits and demerits of phase I radiochemotherapy quality
and safety policies are critiqued considering the current era of rapidly evolving radiation
technologies.
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OPINION
The traditional first-in-human radiochemotherapy study or phase
I investigation often determines the dose and schedule of radiation
and investigational anticancer agent combination. This assess-
ment also paints the initial descriptive palette of adverse events
linked with the co-administration of the two in a dose-dependent
manner. From this parti, we gain an illustrative safety portfolio
for radiation-anticancer agent combinations that allow next step
study of therapeutic response in phase II or III clinical trials.
In an effort to maximize clinical benefit, architects of phase
I radiochemotherapy development programs conduct stepwise
dose-escalated trials of radiation, of anticancer agent(s), or both
together. It has been held in such dose-escalated trials that one
accepts an adverse event or toxicity rate of 33% or less in par-
ticipants, based on the premise that the limited study subject
numbers are largely representative of patient cancer groups shar-
ing common traits. Discovery of a toxicity rate target may be done
by escalating radiation or anticancer agent dose until two of six
(i.e., 33%) enrollees manifest an adverse event, often a toxicity
arising from a pre-determined list. For radiochemotherapy trials,
investigators then drop down to the next lower radiation or anti-
cancer agent dose level to enroll additional patients to establish
a recommended phase II dose and schedule. This is coined the
maximally tolerated dose (MTD). The end product is a radiation-
anticancer agent combination recommended for phase II or III
clinical testing. Here, we focus on stepwise dose-escalated trials but
recognize that other radiation-drug discovery formats are part of
the anticancer clinical development portfolio (Ivanova and Bunce,
2010).
Radiochemotherapy phase I trials are framed by three salient
doctrines: patient wellbeing, principled conduct, and minimized
interruption (Ivy et al., 2010). Indeed, a nod must be given to the
courage of phase I enrollees to have medical treatment, on which
their wellbeing may just depend, involving avant-garde treatment.
Next follows intent to reduce the number of trial participants
exposed to acute and lifelong serious, or even life-threatening,
adverse events. To optimize efficiency, the least number of patients
exposed to subtherapeutic radiation-agent doses merits serious
and respectful scrutiny. When toxicity is used as a measure of
radiochemotherapeutic activity and/or efficacy, responses in phase
I radiochemotherapy studies may occur at a fraction of an investi-
gational anticancer agent’s own active phase II dose and schedule.
To illustrate this point in uterine cervix cancer treatment, gem-
citabine given for radiosensitization [125 mg/m2 (Chavez-Blanco
et al., 2005)] is a fraction (16%) of when gemcitabine is admin-
istered as a single agent [800 mg/m2 (Schilder et al., 2005)] or
combined in a gemcitabine (800 mg/m2)-cisplatin (30 mg/m2)
regimen (Brewer et al., 2006). As another example in uterine
cervix cancer radiochemotherapy, much less (−75%) triapine
(25 mg/m2) is administered for cisplatin radiochemosensitization
(Kunos et al., 2010) than when used as a single agent [96 mg/m2
(Nutting et al., 2009)]. Close-knit phase I research teams are
often able to standardize actual delivered radiation and anticancer
agent dose and schedule as well as radiation treatment portal
design.
But when it comes to large multi-site phase I trials, radia-
tion therapy prescriptions and field designs can be inconsistent
from patient-to-patient, perhaps affecting the toxicity profile of a
radiation-anticancer agent combination. Take for instance the 19
patient study of two-cycle 5-fluorouracil (5FU, 1000 mg/m2/day
over 96 h) and single-cycle bolus mitomycin C (15 mg/m2)
radiochemotherapy (30 Gy in 15 2 Gy fractions) for anal can-
cer (Nigro et al., 1974, 1981; Buroker et al., 1977). In the first
three patients, 5FU was administered 25 mg/kg body weight and
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mitomycin C was given 0.5 mg/kg body weight. No (0/3) sub-
stantial toxicity was reported (Nigro et al., 1974). In the next two
treated patients, serious adverse events occurred. With a toxicity
rate of 40% (2/5) (Nigro et al., 1981), chemotherapy dose was
lowered for the next 14 treated patients. Reversible gastrointesti-
nal toxicity was noted, but the investigators held to an 11% (2/19)
overall toxicity rate (Nigro et al., 1981). A subsequent multi-site
phase III trial of 5FU (1000 mg/m2/day over 96 h) plus mito-
mycin C (10 mg/m2, bolus day 1, 29) radiochemotherapy had
planned adjustments in treatment intensity (Gunderson et al.,
2012). Here, not only was the chemotherapy dose and sched-
ule adjusted, but modifications in radiation delivery involved
change in initial large pelvic field prescribed to 30.6 Gy in 17
1.8 Gy fractions, to a reduced field where the superior margin
was lowered to the inferior level of the sacroiliac joints and pre-
scribed to 14.4 Gy in eight 1.8 Gy fractions. A 10–14 Gy boost
in five to seven 2 Gy fractions followed for T3, T4, N+, or T2
lesions with residual cancer after 45 Gy. After these revisions
to the radiochemotherapy intensity, the study has resulted in a
long-term rate of grade 3 or higher toxicity of 37% (119/325)
for the 5FU/mitomycin C regimen (Gunderson et al., 2012).
Essentially evolving from this study, a phase II trial of 5FU
(1000 mg/m2 over 96 h, day 1, 29) and mitomycin C (10mg/m2,
day 1, 29) radiochemotherapy investigated peer-reviewed dose-
painted intensity modulated radiation therapy (IMRT) (Kachnic
et al., 2013). The initial report has found that an IMRT tech-
nique resulted in a significantly reduced grade 3 or higher gas-
trointestinal toxicity rate of 21% (13/63) (Kachnic et al., 2013).
Taken together, it appears that radiation technology as well as
local investigator radiation portal design, perhaps guided by
peer-review, sways observed radiochemotherapy adverse event
rates.
What ought we to conclude from these clinical lessons
when it comes to the design and the interpretation of phase I
radiochemotherapy clinical trials? In this editorial, the merits and
demerits of phase I radiochemotherapy quality and safety policies
are appraised while mulling over the impact of rapidly evolving
radiation technologies.
RADIATION DOSE AND SCHEDULE
There can be little doubt that both radiation prescription and radi-
ation dose conformity have an influence on the determination of
tolerable radiation-anticancer agent combinations. To ensure safe
and quality radiation in a phase I clinical trial program, it is essen-
tial that radiation dose prescription, treatment volume coverage,
and normal as well as tumor tissue constraints be as uniform as
possible.
From one viewpoint, radiation dose prescriptions have under-
gone careful stepwise evaluations in cancer-specific institutional
trials and multi-center experiences to determine dose that steril-
izes disease at tolerable levels of morbidity. Arbitrary modification
of radiation prescription can unduly influence the appreciated
collage of toxicity from radiation-anticancer agent combinations.
One can appreciate that increasing radiation dose may lead to
unanticipated observable toxicity that would adversely affect clin-
ical judgment of whether a radiation-anticancer agent combina-
tion is tolerable. Likewise, decreasing radiation dose arbitrarily
may result in an under appreciation of toxicity of the intended
study regimen. Unapproved alterations in radiation dose intensity
by participating investigators skews final assessments of whether
radiation-anticancer agent combinations are safe. To encour-
age compliance, radiochemotherapy clinical trials usually include
detailed radiation dose parameters to ensure target volume cov-
erage built around minimum and maximum proportions of the
nominal prescribed dose.
Typically, radiation dose conformity across target volumes
should be as homogenous as possible relative to a recom-
mended prescription dose. In practical terms for dose, overseers
of radiochemotherapy trials rely on treatment plan normalization
points, which can be left to the investigator’s preference and really
only guides display of isodose contours, when assessing radiation
quality. It is recognized that differences between calculation algo-
rithms vary among planning systems up to 30% in extreme cases
(Schuring and Hurkmans, 2008). But one can certainly appreci-
ate that careful monitoring of the placement of the normalization
point, disease location, and overall design of the radiation plan
influence radiation quality. So too, radiation machine output fac-
tors into radiation quality. Quality assurance programs, including
those of phase I radiation centers, have built in daily checks and
balances to ensure accurate radiation dose delivery. As such, vari-
ance in machine output should be minimal, with tolerance ranging
from plus or minus 3%. When it comes to multi-center phase I
radiochemotherapy clinical trials, these tools of radiation quality
(i.e., radiation dose conformity, radiation machine output checks)
are monitored frequently to ensure best practice and style. Logisti-
cally, this conjures up cohesive and centralized teams of physicians
and radiation physicists to ensure utmost care in radiation delivery
among radiochemotherapy trial enrollees.
Protracted delay in treatment schedule modifies assessment of
“risk-adapted” radiation dose. Take for instance a radiation sched-
ule involving daily external beam radiation and co-administration
of an investigational anticancer agent that is also integrated with
ablative brachytherapy. Single external beam treatment day missed
appointments may have minimal impact on overall intensity
of radiation-anticancer agent administration. But multiple day
or multiple week deviations from expected radiation-anticancer
agent courses modifies the radiobiological effect on normal and
cancer cells. Since patient safety is of primary concern in phase I
studies, normal tissue cell recovery and renewal occurring because
of protracted radiation dose delivery could lessen apparent toxic-
ity. Such circumstances may be misleading by under representing
toxicity which would have been witnessed at the intended dose
and schedule.
CONTINUAL RADIATION QUALITY REASSESSMENT
It seems prudent to provide rapid assessment and reassessment of
radiation delivery under phase I clinical trial conditions. Phase I
radiochemotherapy programs are moving toward timely radiation
review prior to turning on the first treatment beam. Computer-
aided plan review and teleconferencing allows near real-time
centralized critique and assurance that radiation protocol guide-
lines are met. Any discrepancies can be discussed, arbitrated, and
accepted by the treating radiation oncologist and by the reviewing
radiation principal investigator or designee. It does seem sensible
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to have at least two unbiased radiation oncologists review and dis-
cuss radiation quality of cases in a phase I program. Rendered
decisions can be communicated to the treating radiation oncolo-
gist and sponsors a culture of on-going learning. Ideally, as new
phase I radiochemotherapy studies develop from prior experience
in a disease, a core group of expert radiation oncologists could
provide longitudinal consistency across the radiation treatment
plans and delivery.
RADIATION FIELD AND/OR VOLUME DESIGN
Radiation safety has rarely been more demanded – or more
newsworthy
For the past 5 years, the American Society for Radiation Oncol-
ogy has promoted recommendations as to how radiation therapy
could be made safer and higher quality. Adverse radiation safety
events (van Sickler, 2005) hurt radiotherapy’s reputation – and
create a dilemma for many early phase radiochemotherapy inves-
tigators who rely on the courage of patients to enroll in their
clinical trials. In radiochemotherapy trials, the incidence of toxic
events often parallels radiation treatment portal size, so when
portal size is large, toxicities increase. After an era of two- and
three-dimensional radiation therapy planning involving sizeable
radiation portals intending gross and occult disease, even small
enlargements in the treatment portal produce more frequent
adverse toxicity events.
Pelvic radiation fields are especially vulnerable. A standardized
four-field box pelvic radiation field expanded in all dimensions by
1 cm can expose up to an added 60% volume of irradiated tissue.
Such a field design modification may substantially elevate total
irradiated volume of bowel and bone marrow, certainly to impact
adverse event rates in these tissues. Other seemingly safe treat-
ment field modifications are at risk, too. In uterine cervix cancer
radiation treatment, a parametrial boost field may be used in clin-
ical situations that call for higher dose to the pelvic sidewalls and
pelvic lymph nodes. Even though a parametrial boost field adds
5.4–9.0 Gy of radiation to the typical 45 Gy of four-field radiation,
investigators must be wary of the rising radiation-related risks to
bowel. For instance, keeping a superior border of the standard-
ized parametrial boost field at a L4/L5 vertebral body junction
and not lowering the border to 1 cm above the inferior margin
of the sacroiliac joint increases the irradiated abdominopelvic vol-
ume by nearly 130%. Since small bowel is more radiosensitive than
other pelvic structures manifests a variety of symptoms that reg-
ister as adverse events, and impacts quality of life in the short and
long-term, any increases in radiation-related exposure could tip
the balance in determining whether a radiation-anticancer agent
combination is safe.
It is difficult to muster much enthusiasm for greater scrutiny
of investigator individualized radiation treatment portal design.
Yet, radiochemotherapy phase I overseers would be unwise to
flee from offering such scrutiny. The tiniest of deviations away
from standard radiation treatment portal design can have sig-
nificant influence over adverse events noted on a clinical trial.
The rate of adverse events directly feeds into the decision making
process of whether a novel radiation-anticancer agent combina-
tion is safe and worthwhile for further testing. That is because
small patient phase I trials serve not only as a source of critical
early development data but also buffer the volatility of the ever-
changing interests of early phase radiation-anticancer agent drug
programs. In an era when many diseases are treated with a multi-
modality approach, it is vital to control all factors in the delivery
of that treatment in order to ensure appropriate analysis of these
new agents.
But there are ways for investigators to manage “risk-adapted”
phase I radiochemotherapy trials. A first step is to standard-
ize quality radiation-anticancer agent delivery. Then, as a sec-
ond step, investigators should explore radiation technologies
that have better prospects for normal tissue tolerance to radi-
ation exposure. The advent of IMRT, helical tomotherapy, and
arc-based or robotic stereotactic ablative radiosurgery (SABR)
has brought new challenges for assurance of radiation quality
and safety. These technologies along with adaptive radiother-
apy and image guided radiotherapy (IGRT) rely on treatment
volume definitions which are still in development in many dis-
ease sites. In radiochemotherapy centers and cooperative groups
known for excellence in the quality delivery of radiation, rapid
review of cases allows for uniform definition of radiation vol-
umes and dose delivered over elapsed times specified in clinical
trial protocols with little variation. Real-time monitoring of these
advanced radiation delivery platforms merits our serious and
respectful scrutiny. Treatment volumes are not as easily defined
by bony anatomy as is seen in 2 and 3-D treatment volumes
and can be variable depending on differing patient anatomy.
Hence these platforms should not earn our uncritical acceptance.
Arguably, these platforms offer expectantly substantial reduction
in radiation-related adverse events but should not be used clin-
ically in deference to rigorous quality assurance by all users.
Also, it is prudent within a single phase I radiochemotherapy
trial to have a uniform radiation platform by all investigators.
Enrolling trial participants into a phase I radiochemotherapy trial
that allows radiation treatment by conventional radiation or by
IMRT would cloud the interpretation of observed radiation-drug
adverse events, possibly raising issues of falsely concluding a safe
relationship exists when it truly may not. Mixing technologies
on a phase I radiochemotherapy trial may also invalidate the
historical radiation-specific technology adverse event data upon
which the trial was predicated. Observed toxicity on down-the-
line phase II or phase III studies may also be influenced by “any”
form radiation delivery. More study is needed and guidelines for
safety and quality assurance are emerging for these new technolo-
gies and utilization in phase I radiochemotherapy studies should
only be considered once these guidelines are confirmed in other
venues.
CONCLUSION
Making radiation-anticancer agent discovery safer and of optimal
quality is the goal of phase I radiochemotherapy programs. Imple-
menting the layers of quality control such as dose checks, timeta-
bles, uniformity in treatment portal/treatment volume design, and
brachytherapy application, and with timely critical feedback are
musts in high-performing phase I radiochemotherapy programs.
In the context of radiochemotherapy, the architects of clinical tri-
als must layout plans intended to balance the safe selection and
concise use of radiation-anticancer agent combinations.
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